Aliski William Form 3/A

October 09, 2	018									
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549							M OMB A	OMB APPROVAL		
							OMB Number:	3235-0104		
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF								January 31, 2005		
SECURITIES							Estimated average			
		17(a) of	t to Section 16(a) of the the Public Utility Holdi 0(h) of the Investment C	ng Company	y Act of 193		burden hou response on	rs per 0.5		
(Print or Type R	esponses)									
1. Name and Address of Reporting Person <sup>*</sup>			Statement	3. Issuer Name <b>and</b> Ticker or Trading Syr Ultragenyx Pharmaceutical Inc. [R						
Aliski Wi	lliam		(Month/Day/Year)	6 5		L	-			
(Last)	(First) (	(Middle)	01/30/2014	4. Relationship of Reporting 5. If			Amendment, Date Original l(Month/Day/Year)			
C/O ULTRAGENYX				(Check all applicable)			01/30/2014			
PHARMACI INC., 60 L		TOURT		(Check		,				
IIIC.,A 00 L				X Directo Officer	or 10% Other	Owner				
	(Street)				w) (specify bel	ow) Filir _X_	ndividual or Join ng(Check Applica Form filed by On	ble Line)		
NOVATO,Â	CAÂ 94949	)					on Form filed by Mor orting Person	e than One		
(City)	(State)	(Zip)	Table I - I	Non-Deriva	tive Securiti	ies Benefi	cially Owned	I		
1.Title of Secur (Instr. 4)	ity		2. Amount of Beneficially (Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature o Ownership (Instr. 5)	of Indirect Benef	icial		
Common Sto	ock		36,930		Ι	By trust	(1)			
Reminder: Repo owned directly o		e line for ea	ach class of securities benefic	ially S	SEC 1473 (7-02	2)				
	informa required	tion conta d to respo	pond to the collection of ained in this form are no ond unless the form disp MB control number.	t						
Т	able II - Deriv	ative Secu	rities Beneficially Owned (a	e.g., puts, calls	, warrants, op	tions, conve	rtible securities			
1. Title of Deriv	vative Security	2. Dat	te Exercisable and 3. Title a	and Amount of	4.	5.	6. Natur	e of Indirect		

2. Date Exercisable and	3. Title and Amount of	4.	5.	6. Nature of Indirect
Expiration Date	Securities Underlying	Conversion	Ownership	Beneficial Ownership
(Month/Day/Year)	Derivative Security	or Exercise	Form of	(Instr. 5)
	(Instr. 4)	Price of	Derivative	
		Derivative	Security:	
	Expiration Date	(Month/Day/Year) Derivative Security	Expiration Date (Month/Day/Year)Securities Underlying Derivative Security (Instr. 4)Conversion or Exercise	Expiration Date (Month/Day/Year)Securities Underlying Derivative Security (Instr. 4)Conversion or Exercise Price ofOwnership Form of Derivative

### Edgar Filing: Aliski William - Form 3/A

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Series A Preferred Stock	(2)	(2)	Common Stock	266,343	\$ 0	Ι	By trust (1)

# **Reporting Owners**

<b>Reporting Owner Name / Address</b>			Relationships				
	Direc	ctor	10% Owner	Officer	Other		
Aliski William C/O ULTRAGENYX PHARMACEUTICAL INC 60 LEVERONI COURT NOVATO, CA 94949	Â	х	Â	Â	Â		
Signatures							
/s/ Ruben A. Garcia, attorney-in-fact 10/09/201	18						
**Signature of Reporting Person Date							

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These shares are held in a trust for the benefit of the reporting person's spouse and children. The reporting person's spouse and nephew are trustees of the trust.

Each share of Series A Convertible Preferred Stock is convertible into Common Stock at any time and automatically converts into Common Stock on a 1-for-3.1345 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and has

(2) no expiration date. The number of underlying shares of Common Stock reported in Column 3 does not reflect this 1-for-3.1345 reverse stock split, pursuant to which each share of Series A Convertible Preferred Stock will become convertible into 0.3190 of a share of Common Stock.

### Â

### **Remarks:**

This amendment is filed to report shares held in a trust for the benefit of the reporting person'sÂ

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.